You are here
Lymphocyte Targeting by Peptide-Drug Conjugates
Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43AI052556-01A1
Agency Tracking Number: AI052556
Amount:
$100,000.00
Phase:
Phase I
Program:
SBIR
Solicitation Topic Code:
N/A
Solicitation Number:
PHS2004-2
Timeline
Solicitation Year:
2004
Award Year:
2004
Award Start Date (Proposal Award Date):
N/A
Award End Date (Contract End Date):
N/A
Small Business Information
ADMUNEX THERAPEUTICS, INC.
3514 CLINTON PKY, STE A-111
LAWRENCE, KS
66047
United States
DUNS:
N/A
HUBZone Owned:
No
Woman Owned:
No
Socially and Economically Disadvantaged:
No
Principal Investigator
Name: LEO Gu
Phone: (408) 245-0003
Email: IGU@ADMUNEX.COM
Phone: (408) 245-0003
Email: IGU@ADMUNEX.COM
Business Contact
Name: THOMAS MALEFYT
Phone: (831) 659-4336
Email: tmalefyt@admunex.com
Phone: (831) 659-4336
Email: tmalefyt@admunex.com
Research Institution
N/A
Abstract
DESCRIPTION (provided by applicant): The long-term objective of this work is to design bi-functional peptide-drug conjugates that specifically target leukocytes. The peptide sequences are derived from ICAM-1 and bind to LFA-1 on activated leukocytes. The
* Information listed above is at the time of submission. *
